Evidence map›Paper›PMID 32054730›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2020

A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.

Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D Nelson, Sarah M Dry, Jackie Hernandez and 7 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06593899 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

The Total Neoadjuvant Therapy for Hypofractionated Radiotherapy Combined with AI Regimens in Soft Tissue Sarcoma of the Extremities: a Phase 2 Single Arm Multicenter Study

TypeinterventionalSponsorFujian Medical University Union HospitalRan2024 to 2026Enrolled51ConditionsSoft Tissue SarcomasArmsHypofractionated Radiotherapy, 3 cycles of AI
NCT07265661 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Surgical Timing After Preoperative Hypofractionated Radiotherapy for Patients With Primary Localized Soft Tissue Sarcoma of the Extremity and Trunk: a Randomized Phase 2 Clinical Trial

TypeinterventionalSponsorItalian Sarcoma GroupRan2026 to 2035Enrolled142ConditionsSoft Tissue Sarcoma of the Trunk and ExtremitiesArmshypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 1-2 weeks after treatment, hypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 4-6 weeks after treatment
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Anusha KalbasiDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California. anushakalbasi@mednet.ucla.edu fceilber@mednet.ucla.edu.
Mitchell KamravaCedars-Sinal Medical Center, Los Angeles, California.
Fang-I ChuDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0003-3336-9333
Donatello TelescaDepartment of Biostatistics, University of California Los Angeles Fielding School of Public Health, Los Angeles, California.
Ritchell Van DamsDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0002-1124-2676
Yingli YangDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.
Dan RuanDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.
Scott D NelsonUniversity of California Los Angeles Jonsson Comprehensive Cancer Center Sarcoma Program, Los Angeles, California.
Sarah M DryUniversity of California Los Angeles Jonsson Comprehensive Cancer Center Sarcoma Program, Los Angeles, California.
Jackie HernandezDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.
Bartosz ChmielowskiUniversity of California Los Angeles Jonsson Comprehensive Cancer Center Sarcoma Program, Los Angeles, California.
Arun S SinghDivision of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California.
Susan V BukataUniversity of California Los Angeles Jonsson Comprehensive Cancer Center Sarcoma Program, Los Angeles, California.
Nicholas M BernthalUniversity of California Los Angeles Jonsson Comprehensive Cancer Center Sarcoma Program, Los Angeles, California.
Michael L SteinbergDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0002-4292-5824
Joanne B WeidhaasDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, California.
Fritz C EilberDivision of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California. anushakalbasi@mednet.ucla.edu fceilber@mednet.ucla.edu.ORCID 0000-0003-3336-9333
University of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionR01CA238998 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEIDHAAS, JOANNE B · 2019 to 2023
$1.8M
NCI NIH HHS L30 CA220808NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA238998
6 · The paper itself

Abstract

purposeIn a single-institution phase II study, we evaluated the safety of a 5-day dose-equivalent neoadjuvant radiotherapy (RT) regimen for high-risk primary soft tissue sarcoma. PATIENTS AND

methodsPatients received neoadjuvant RT alone (30 Gy in five fractions) to the primary tumor with standard margins. The primary endpoint was grade ≥2 late-radiation toxicity. Major wound complications, local recurrences, and distant metastases were also examined. In exploratory analysis, we evaluated germline biomarkers for wound toxicity and the effects of the study on treatment utilization.

resultsOver 2 years, 52 patients were enrolled with median follow-up of 29 months. Seven of 44 evaluable patients (16%) developed grade ≥2 late toxicity. Major wound complications occurred in 16 of 50 patients (32%); a signature defined by 19 germline SNPs in miRNA-binding sites of immune and DNA damage response genes, in addition to lower extremity tumor location, demonstrated strong predictive performance for major wound complications. Compared with the preceding 2-year period, the number of patients treated with neoadjuvant RT alone at our institution increased 3-fold, with a concomitant increase in the catchment area.

conclusionsA shorter 5-day neoadjuvant RT regimen results in favorable rates of wound complications and grade ≥2 toxicity after 2-year follow-up. Five-day RT significantly increased utilization of neoadjuvant RT at our high-volume sarcoma center. With further validation, a putative germline biomarker for wound complications may guide safer RT utilization.

Indexed as

AgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMicroRNAsMiddle AgedNeoadjuvant TherapyPatient SafetyPolymorphism, Single NucleotideRadiotherapy DosageSarcomaSoft Tissue NeoplasmsTreatment OutcomeWounds and InjuriesBiomarkers, TumorMicroRNAs

Identifiers

PMID32054730
PMCPMC7189949
OpenAlexW3005933253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.